Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Eli Lilly and Company recently completed a Phase 3 study titled A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2). The study aimed to assess the safety and effectiveness of orforglipron, a once-daily oral treatment, in reducing body weight among adults with obesity or overweight and type 2 diabetes.
Intervention/Treatment: The study tested orforglipron, an oral medication designed to aid weight loss in individuals with obesity or overweight and type 2 diabetes. The treatment was compared against a placebo to evaluate its efficacy.
Study Design: This interventional study employed a randomized, parallel assignment model with double masking, meaning both participants and investigators were unaware of whether the treatment or placebo was administered. The primary purpose was to assess treatment effectiveness.
Study Timeline: The study commenced on May 15, 2023, and was completed by September 17, 2025, when the last update was submitted. These dates are crucial as they mark the progression and completion of the study, providing a timeline for investors to gauge the development of the treatment.
Market Implications: The completion of this study could positively impact Eli Lilly’s stock performance, as successful results may enhance investor confidence and market position in the competitive diabetes and obesity treatment sector. With growing demand for effective weight management solutions, Eli Lilly’s advancements could position it favorably against competitors.
The study is now completed, with further details available on the ClinicalTrials portal.